Click here to view online. Add this email to your safelist.
Siliq (brodalumab) approved by the US FDA for adult patients with moderate-to-severe plaque psoriasis
16 February 2017
AstraZeneca’s partner Valeant Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Siliq (brodalumab) injection for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
